Latest Interferon Stories
A pair of drugs frequently used to help treat hepatitis C patients could be used to help treat Middle East Respiratory Syndrome (MERS) coronavirus, according to research published online earlier this week by the journal Nature Medicine.
National Institutes of Health (NIH) scientists report that a combination of two licensed antiviral drugs reduces virus replication and improves clinical outcome in a recently developed monkey model of Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
Researchers at the Salk Institute for Biological Studies have discovered a powerful mechanism by which viruses such as influenza, West Nile and Dengue evade the body's immune response and infect humans with these potentially deadly diseases.
Monash University researchers have gained new insight into the early stages of our immune response, providing novel pathways to develop treatments for diseases from multiple sclerosis to cancer.
Researchers at UT Southwestern Medical Center report the identification of a new cellular source for an important disease-fighting protein used in the body's earliest response to infection.
The group of genetic conditions known as spinocerebellar ataxias currently have no treatment or cure and are always fatal, in the case of affected children at an early age.
When DNA that turns up in the wrong place in mammalian cells, the innate immune system reacts by secreting interferons.
Hepadnaviruses can cause liver infections in humans and animals. The two recognized genera are Genus Orthohepadnavirus and Genus Avihepadnavirus. It has a small genome of partially double-stranded, partially single stranded circular DNA. It is a group 7 virus that uses an RNA intermediate during replication. Most people who come into contact with the virus are able to clear the infection alone although some cannot and usually progress to fulminant hepatitis. It can cause sever liver...